Sun Pharma hits over 5-yr high on hopes of robust revenue growth in Q2

Motilal Oswal Securities remains positive on Sun Pharma due to investments in the global Specialty portfolio improving overall profitability

Shares of Sun Pharmaceutical Industries hit an over five year high of Rs 846.80, up 2 per cent on the BSE in Wednesday;s intra-day trade, on expectation of strong revenue growth supported by healthy specialty as well as healthy domestic performance. The stock of the drug company was trading at its highest level since August 2016.

The board of directors of Sun Pharma is scheduled to meet on November 02, 2021 to consider and approve unaudited financial results of the company for the quarter and half year ended September 30, 2021.

"In Q2FY22, Sun Pharma is likely to